
State of the biotech sector-2007

Stacy Lawrence

The biotech sector as a whole narrowed its loss by 64% to \$2.7 billion, according to consultants Ernst & Young. This is the closest the industry has come to breaking even (a trend that agrees with *Nature Biotechnology*'s independent public biotech analysis, p. 753). The number

Number of biotech companies


The European and Asian sectors both continued to grow; they were the only regions where private firms increased in number.



Source: Ernst & Young

Cash in the bank at US public biotechs

The number of the companies with >5 years of cash declined, and more biotechs now have <2 years of cash in the bank.



of public biotechs jumped by double digits in every region except for Canada. Cash reserves dwindled, however, perhaps foreshadowing a continued financing slowdown this year. Still, mergers and acquisitions and partnership valuations were at record highs in 2007.


Global overview of biotech companies

2006	2007	Percent change	
78.4	84.8	8%	
29.9	31.8	7%	
7.4	2.7	-64%	
743	798	7%	
3,717	3,616	-3%	
	78.4 29.9 7.4 743	78.4 84.8 29.9 31.8 7.4 2.7 743 798	

Source: Ernst & Young

Alliances and mergers

Last year, M&A shadowed the partnership value spike first seen in 2006.



Partnership data includes all potential value. Source: Ernst & Young

2007 US public company data by region

Region	Number of public companies*	Market cap* (\$ millions)	Revenue* (\$ millions)			Cash and short-term investments* (\$ millions)	Total assets* (\$ millions)
				R&D* (\$ millions)	Net loss or income* (\$ millions)		
New England	62 (7%)	65,153 (5%)	11,399 (17%)	4,572 (3%)	(755) (–44%)	8,554 (13%)	26,832 (1%)
San Diego	42 (5%)	23,695 (24%)	3,229 (18%)	1,975 (44%)	(1,468) (20%)	4,992 (30%)	9,330 (14%)
New Jersey	32 (7%)	29,668 (-7%)	3,248 (31%)	1,172 (23%)	(151) (-75%)	4,592 (25%)	9,172 (6%)
Mid-Atlantic	22 (5%)	6,762 (2%)	687 (-61%)	762 (–34%	(604) (–4%)	1,452 (-8%)	3,345 (4%)
Southeast	23 (10%)	2,819 (-15%)	253 (0%)	773 (201%)	(769) (120%)	700 (-11%)	1,122 (–9%)
New York State	28 (0%)	12,106 (28%)	1,528 (0%)	3,635 (372%)	(309) (–57%)	2,695 (11%)	4,251 (4%)
Midwest	11 (22%)	1,331 (53%)	40 (-12%)	134 (76%)	(195) (91%)	337 (84%)	293 (31%)
Pacific Northwest	14 (0%)	2,876 (-11%)	149 (-12%)	567 (21%)	(607) (15%)	690 (-11%)	1,056 (0%)
Los Angeles/Orange County	21 (24%)	58,202 (–36%)	18,899 (5%)	4,558 (–22%)	2,935 (47%)	8,470 (14%)	41,068 (-1%)
North Carolina	9 (-10%)	1,772 (–9%)	428 (38%)	275 (30%)	(118) (23%)	557 (44%)	935 (27%)
Pennsylvania/Delaware Valley	5 (0%)	8,547 (12%)	2,250 (7%)	698 (3%)	(429) (201%)	2,170 (40%)	5,018 (14%)
Texas	13 (8%)	1,481 (-12%)	167 (10%)	233 (4%)	(278) (6%)	429 (73%)	695 (50%)
Colorado	4 (-20%)	919 (7%)	92 (-69%)	131 (-44%)	(102) (47%)	290 (181%)	365 (136%)
Utah	2 (0%)	2,219 (53%)	278 (71%)	142 (-7%)	(27) (-82%)	339 (-14%)	735 (47%)
Other	11 (-8%)	4,489 (90%)	443 (1%)	114 (-32%)	(38) (-55%)	175 (-41)	734 (3%)

*Percentages indicate change from 2006. New England includes CT, ME, MA, NH, RI; Mid-Atlantic includes MD, VA, DC; Southeast includes AL, AR, FL, GA, KY, LA, TN, SC; Midwest includes IL, MI, OH, WI; Pacific Northwest includes OR, WA; Other includes HI, MN, MO, NE, NV, OK and SD. Source: Ernst & Young

Stacy Lawrence is senior writer at BioCentury Publications